Save the date! 📅 Our annual client event, Certainty by Certara, is coming to Europe for the first time this fall! https://lnkd.in/ejDR83h5 Join us 29-30 October 2024 in Mainz, Germany for an engaging event where experts and scientists in biosimulation, clinical pharmacology, regulatory science, AI, and software development will come together to share strategies, best practices, and lessons learned for improving greater certainty in drug development. The areas of expertise and session themes include: - Biosimulation for improved success across the development lifecycle - Digital data flows from protocol design through approvals - The value of Model Informed Drug Development from discovery to first in human - Applying Generative AI to solve drug development challenges For our power technology users interested in learning about the latest features available in the Certara platform, we are offering one-day user group meetings on Wednesday, 30 October for Phoenix️™ and Pinnacle 21. Learn more and reserve your spot: https://lnkd.in/ejDR83h5 We can't wait to see you in Mainz! #CertaintyEurope #CertaraCertainty #DrugDevelopment
Certara’s Post
More Relevant Posts
-
Looking forward to participate as lecturer in this ECMP seminar. The topic is the application of AI to immunogenicity risk prediction. #immunogenicity #predictiontools #riskassessment #riskmitigation
Registration is open for the ECPM 1-day Seminar on "AI across Drug Discovery and Development" 👉 Join us in exploring the current and future applications and opportunities for artificial intelligence in drug development. 👉 Be part of an exciting experience with around 100 course participants. 👉 Save your spot! ➡ Registration: https://lnkd.in/eYuvsVHa Mark your calendars for an immersive one-day seminar on February 8, 2024, investigating the synergy of AI in drug development. Delve into the forefront of biologic safety profiles, explore pharmacovigilance with AI, unlock the potential of synthetic data, expedite market authorization, and navigate the legal landscape of AI in Pharma. We look forward to welcoming you soon: Annette Mollet, Thomas Szucs, Nastazja Monika Laskowski, Nicola Liversidge. ➡ Date: February 8, 2024 ➡ Venue: University of Basel, Biozentrum ➡ More information: https://lnkd.in/efa_f4UB Special thanks to our speakers and partners: Anna Bauer-Mehren, Simone Manso, Laura Inés Salazar Fontana, Nandish Poluru, Andrew Bate, Khaled El Emam, Alessandro Blasimme, Ryan Abbott. #continuingmedicaleducation #drugdevelopment #ECPM
-
𝗧𝗵𝗲 𝟭𝟯𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗛𝗼𝘂𝘀𝗲 𝗼𝗳 𝗣𝗵𝗮𝗿𝗺𝗮 𝗮𝗻𝗱 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 on September 3, 2024, in #FrankfurtamMain is coming up - and we are attending! With Dr. Daniel-Timon Spanka talking about data quality and increased efficiency, he will discuss how our AI-software #Meteor transforms clinical data reviews and supports the work of data management experts in the pharmaceutical industry and in CROs. Currently, a lot of time is required to manually check all texts collected in clinical studies. Meteor presents a valuable solution with efficient clinical data reviews, saving time and reducing error rates significantly with the help of AI. Catch us in Frankfurt and schedule a meeting with our experts in data science to discuss the use of artificial intelligence in medical research. Hanno Härtlein Alex Heinz Dr. Paul W. Dr. Benedikt Linder Dr. Juan M. Guerra #HouseofPharma #Healthcare #ClinicalTrials
-
-
In this thought provoking video, Prof. Reddanna Pallu, Executive President of FABA, emphasizes the need for stronger collaboration in the field of drug discovery. His insights shed light on the importance of translational research in bridging lab findings and clinical applications. A must-watch for anyone interested in the future of biotech and healthcare! 🎥 Watch the full video here: https://lnkd.in/ggUFEatu #DrugDiscovery #TranslationalResearch #DDD2023 #FABA
-
Data volume, variety and velocity continue to accelerate across all areas of drug development. Preclinical scientists have the same needs as clinical scientists to access, visualize & make informed decisions using preclinical data. Certara helps solve this problem with the "Easy Button" for preclinical data insights. Built by scientists for scientists, SEND Explorer® visualizes and analyzes preclinical data in the SEND format for improved scientific understanding and collaboration resulting in faster drug development. A familiar problem - learn more: https://bit.ly/42KCyM1
-
Bioinformatics Consultant @Clarivate | Bioinformatics | Data Scientist | Pharma Industry | Python 🧬
🚀 Exciting News! We are thrilled to announce our next webinar on Drug Repurposing, hosted by Sarah Bonnin, Marti Bernardo Faura and myself. Do not miss out on this opportunity to stay at the forefront of medical advancements. Whether you are a researcher, healthcare professional, or just curious about the future of medicine, this webinar is for you! You will also have the chance to submit your questions 🤔 📅 Save the Date: 19 September 2023, 3:00 pm GMT Summer Time 📌 Mark Your Calendar: https://lnkd.in/erJ-J7xf What you can expect: 💊 How does drug repurposing differ from a traditional drug discovery pipeline? 🌟 Benefits of drug repurposing 🖥 Current computational methods for drug repurposing 🌍 Challenges and future perspectives We hope to see you there! #DrugRepurposingWebinar #InnovationInMedicine #HealthcareRevolution
-
The synergy between technological innovation and regulatory advancement. At the 15th Annual Drug Discovery Innovation Forum in Berlin Sept. 4-5, Karen Sayal - MD PhD consultant clinical oncologist and industry-first scientist in AI-driven Clinical Translation and Clinical Development at Recursion - will give a talk on the synergistic advancement of AI-enabled drug discovery and regulation. She'll discuss: ◾ How industrialising drug development is unveiling hidden biological complexities to propel a paradigm shift in treating human disease. ◾ How technology-driven discovery is synergistic to the needs of our evolving next-generation regulatory ecosystem. ◾ And how we can achieve seamless interoperability between the needs of developing and deploying AI technologies and the needs of regulation through pragmatic bipartisan dialogue and coordinated evolution. Learn more & register: https://lnkd.in/d8EFpTuh #ai #ddif #ddif2024 #drugdiscovery #innovation #tech #techbio #regulation
-
-
Looking forward to speaking about LLMs and different optimization techniques during the Generative AI session today at PharmaDS. #generativeai #llm
📍PharmaDS 2024: It's the last day to register! Join us at the University of Connecticut or virtually for a two-day event on March 18-19, 2024. Preview our speaker lineup for Session 2: Clinical Operations 🔜 Integration of AI in Clinical Trials: Benefits, Risks, and Precautions by Sidd Bhattacharya, Partner @ PWC 🔜 Supporting Physicians to Become Clinical Researchers by Natalie (Vargas) Monegro, MBA MPH, Director of Clinical Trial Diversity & Patient Inclusion @ Abbvie 🔜 High-Throughput Target Trial Emulation with Real-World Data for Alzheimer’s Disease Drug Repurposing and Beyond by Chengxi Zang, Instructor @ Cornell University 🔗 Register now: https://lnkd.in/gWCa8NAr #datascience #analytics #ai #pharma #biotech #drugdevelopment #conference
-
One of our biggest announcements - Apheris is powering the world's #1 drug discovery AI consortium with JnJ & Abbive (and more PharmaCos in the pipeline to join) 👩🔬 💊 DeepMind led the way with AlphaFold models predicting protein-folding to unprecedented accuracy. The next step in AI-powered drug discovery is understanding not just how one protein folds, but how molecules interact. Yet the highest quality data for this is proprietary data of large pharmaceutical companies. Apheris is now enabling leading drug discovery AI model builders to train their models in a federated manner on top PharmaCo data. All while protecting both the data and model IP of all the collaborating partners. Bringing research to industry - we're a step closer to delivering real patient outcomes with these breakthroughs 💚 Read more: https://lnkd.in/eh4rxcVi
📣 Apheris is proud to announce its support for the AI in Structural Biology Consortium 💡 Consortium brings together biopharma leaders AbbVie and Johnson & Johnson Innovative Medicine to collaboratively train AI models on their proprietary protein structure data – while protecting data confidentiality. 👉 The challenge: Drug Discovery models often fail to generalize well due to the limited diversity of publicly available training data. The largest and most valuable molecular datasets are owned by biopharma companies that need to protect their intellectual property 💎 The solution: Collaborative AI model training on proprietary pharmaceutical data using governed, private, and secure federated learning with Apheris. Our goal is to leverage the power of AI to accelerate molecule design and achieve greater precision in X-ray crystallography while protecting valuable data. Special thanks to Tommaso Mansi, Sujata Sharma, Steven Elmore, Bryan Rutsch, Scott Palmer, and José-Tomás (JT) Prieto, PhD, who have been key in getting this started. 🔗 Learn more about AI in Structural Biology Consortium: https://hubs.li/Q02y4Pr90 #FederatedLearning #AIGovernance #AIDrugDiscovery #Pharma #DataProtection
-
-
Welcome to meet and discuss how to make Drug Discovery more faster and cost effective in the future
Orion Day
lyyti.fi
-
𝐔𝐬𝐢𝐧𝐠 𝐀𝐈 𝐭𝐨 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 Amin Rostami-Hodjegan and Piet Van Der Graaf delve into how AI can tackle the extremes of data abundance and scarcity. While optimizing target affinity for virtual compounds is essential, the true breakthrough lies in combining pharmacokinetics (PK), desired effects, and minimizing unwanted issues. Discover how PBPK and QSP models provide holistic insights and predict clinical outcomes, accelerating the drug discovery process. Are you ready to transform your research? 👉𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞: https://lnkd.in/gJTNeMjc 👉𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://lnkd.in/dd4w2vnF 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gv7R4SPi #DrugDiscovery #AI #Pharmacokinetics #PBPK #QSP #ClinicalOutcomes #BiomedicalResearch #Innovation #Healthcare #PharmaTech #ArtificialIntelligence #Biotech #Pharma #DataScience #FutureOfMedicine
